42 results on '"Grünhagen, Dirk"'
Search Results
2. Assessing patients’ needs in the follow-up after treatment for colorectal cancer—a mixed-method study
- Author
-
Voigt, Kelly R., de Bruijn, Esmee A., Wullaert, Lissa, Witteveen, Léon, Verhoef, Cornelis, Husson, Olga, and Grünhagen, Dirk J.
- Published
- 2024
- Full Text
- View/download PDF
3. Extrahepatic perfusion and incomplete hepatic perfusion after hepatic arterial infusion pump implantation: incidence and clinical implications
- Author
-
Filipe, Wills F., Buisman, Florian Buismanz, Koerkamp, Bas Groot, Grunhagen, Dirk J., Homs, Marjolein Y.V., Verhoef, Cornelis, Moelker, Adriaan, Graven, Laura, Franssen, Stijn, Gobardhan, Paul D., Loosveld, Olaf J.L., Pool, Stefan, Mieog, J. Sven D., Speetjens, Frank M., Rietbergen, Daphne D.D., Burgmans, Mark C., Doornesbosch, Pascal G., Patijn, Gijs A., de Groot, Jan Willem B., Meier, Mark A.J., Oostdijk, Ad H.J., Boluis, Karen, Grootscholten, Cecile, klompenhouwer, Elizabeth G., Kok, Niels F.M., kuhlmann, Koert, F.D., Krul, Myrtle F., Versleijen, Michelle W.J., Bruijnen, Rutger C.G., Hagendoorn, Jroen, Lam, Marnix G.E.H., Roodhart, Jeanine M.L., Bennink, Roel J., van Delden, Otto M., Swijnenburg, Rutger-Jan, Buffart, Tineke E., Borel Rinkes, Inne H.M., Cercek, Andrea, Kemeny, Nancy E., Peter Kingham, T., D’Angelica, Michael, van Bommel, Christian P.H., van Doorn, Leni, Ayez, Ninos, Vermaas, Maarten, Nieuwenhuijse, Vincent B., Buisman, Florian E., Grünhagen, Dirk J., Bolhuis, Karen, Doornebosch, Pascal G., Hagendoorn, Jeroen, Harmsen, Paul, Klompenhouwer, Elizabeth G., Outmani, Loubna, Swijnenburg, Rutger Jan, Kuhlmann, Koert F.D., and Groot Koerkamp, Bas
- Published
- 2024
- Full Text
- View/download PDF
4. Outcomes of liver surgery: A decade of mandatory nationwide auditing in the Netherlands
- Author
-
Patijn, Gijs A., Torrenga, Hans, van Heek, N. Tjarda, Oosterling, Steven J., de Graaff, Michelle R., Klaase, Joost M., Dulk, Marcel den, Buis, C.I., Derksen, Wouter J.M., Hagendoorn, Jeroen, Leclercq, Wouter K.G., Liem, Mike S.L., Hartgrink, Henk H., Swijnenburg, Rutger-Jan, Vermaas, M., Belt, Eric J. Th, Bosscha, Koop, Verhoef, Cees, Olde Damink, Steven, Kuhlmann, Koert, Marsman, H.M., Ayez, Ninos, van Duijvendijk, Peter, van den Boezem, Peter, Manusama, Eric R., Grünhagen, Dirk J., and Kok, Niels F.M.
- Published
- 2024
- Full Text
- View/download PDF
5. The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial)
- Author
-
Holmberg, Carl-Jacob, Zijlker, Lisanne P., Katsarelias, Dimitrios, Huibers, Anne E., Wouters, Michel W.J.M., Schrage, Yvonne, Reijers, Sophie J.M., van Thienen, Johannes V., Grünhagen, Dirk J., Martner, Anna, Nilsson, Jonas A., van Akkooi, Alexander C.J., Ny, Lars, van Houdt, Winan J., and Olofsson Bagge, Roger
- Published
- 2024
- Full Text
- View/download PDF
6. Technical considerations for isolated limb perfusion: A consensus paper
- Author
-
Hayes, Andrew J., Coker, David J., Been, Lukas, Boecxstaens, Veerle WSM., Bonvalot, Sylvie, De Cian, Franco, de la Cruz-Merino, Luis, Duarte, Carlos, Eggermont, Alexander, Farricha, Victor, Fiore, Marco, Grünhagen, Dirk, Grützmann, Robert, Honoré, Charles, Jakob, Jens, Hocevar, Marko, van Houdt, Winan, Klauzner, Joseph, Kettelhack, Christoph, Märten, Angela, Martinez-Said, Hector, Matter, Maurice, Michot, Audrey, Niethard, Maya, Pennacchioli, Elisabetta, Podleska, Lars E., Rabago, Gregorio, Rastrelli, Marco, Reijers, Sophie, Ribeiro, Matilde, Schwarzbach, Matthias, Snow, Hayden A., Spacek, Miroslav, Stoldt, Stephan, Testori, Alessandro, Zoras, Odysseas, and Olofsson Bagge, Roger
- Published
- 2024
- Full Text
- View/download PDF
7. Hospital variation and outcomes after repeat hepatic resection for colorectal liver metastases: a nationwide cohort study
- Author
-
Torrenga, Hans, de Graaff, Michelle R., Klaase, Joost M., den Dulk, Marcel, te Riele, Wouter W., Hagendoorn, Jeroen, van Heek, N. Tjarda, Vermaas, M., Belt, Eric J. Th., Bosscha, Koop, Slooter, Gerrit D., Leclercq, Wouter K.G., Liem, Mike S.L., Mieog, J. Sven D., Swijnenburg, Rutger-Jan, van Dam, Ronald M., Verhoef, Cees, Kuhlmann, Koert, van Duijvendijk, Peter, Gerhards, Michael F., Gobardhan, Paul, van den Boezem, Peter, Manusama, Eric R., Grünhagen, Dirk J., and Kok, Niels F.M.
- Published
- 2024
- Full Text
- View/download PDF
8. Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis
- Author
-
Stassen, Robert C, Maas, Carolien C H M, van der Veldt, Astrid A M, Lo, Serigne N, Saw, Robyn P M, Varey, Alexander H R, Scolyer, Richard A, Long, Georgina V, Thompson, John F, Rutkowski, Piotr, Keilholz, Ulrich, van Akkooi, Alexander C J, Verhoef, Cornelis, van Klaveren, David, and Grünhagen, Dirk J
- Published
- 2024
- Full Text
- View/download PDF
9. Association of modified textbook outcome and overall survival after surgery for colorectal liver metastases: A nationwide analysis
- Author
-
Manusama, Hans Torrenga E., van Heek, Tjarda N., Oosterling, S.J., Voigt, Kelly R., de Graaff, Michelle R., Verhoef, Cornelis, Kazemier, Geert, Swijneburg, Rutger J., Mieog, J.Sven D., Derksen, Wouter J.M., Buis, Carlijn I., Gobardhan, Paul D., Dulk, Marcel den, van Dam, Ronald M., Liem, Mike S.L., Leclercq, Wouter K.G., Bosscha, Koop, Belt, Eric J.T., Vermaas, Maarten, Kok, Niels F.M., Patijn, Gijs A., Marsman, H.M., van den Boezem, Peter B., Klaase, Joost M., and Grünhagen, Dirk J.
- Published
- 2024
- Full Text
- View/download PDF
10. Combined portal and hepatic vein embolisation in perihilar cholangiocarcinoma
- Author
-
Chevallier, Patrick, Wigmore, Stephen, Newhook, Timothy, Vauthey, Jean-Nicolas, Memeo, Riccardo, Dasari, Bobby VM., Braunwarth, Eva, Aldrighetti, Luca, Andorrà, Esteban Cugat, Arntz, Pieter, Arslan, Bulent, van Baardewijk, Laurens, Baclija, Ivan, Ball, Chad, Barbier, Louise, Bednarsch, Jan, Bemelmans, Marc, Bent, Clare, van den Bergh, Frans, Billingsley, Kevin, Binkert, Christoph, Björnsson, Bergthor, de Boer, Marieke T., Bokkers, Reinoud P.H., de Boo, Diederick, Garcia Borobia, Francisco Javier, Braat, Dries, Breen, David, Breitenstein, Stefan, Brousseau, Karine, Bruijnen, Ruther, Bruners, Philipp, Bruns, Christiane, Bunck, Alexander, Burgmans, Mark, Cappelli, Alberta, Carling, Ulrik, de Carvalho, Luis Abreu, Cha, Charles, Chan, Benjamin, Chand, Belinda, Chapelle, Thiery, De Cobelli, Franceso, Coubeau, Laurent, Criado, Eva, Croagh, Daniel, D'Hondt, Mathieu, van Dam, Ronald, Damink, Steven Olde, Davis, Rob, Delle, Martin, Denys, Alban, Deprez, Fabrice, Detry, Olivier, Dewulf, Maxime, Dili, Alexandra, Dixon, Matthew, Díaz-Nieto, Rafael, Erdmann, Joris I., Fernando, Rukshan, Font, Jaume Codina, Fouraschen, Suomi, François, Olivier, Fretland, Åsmund A., Fundora, Yilian, Gadani, Sameer, Gallinger, Steven, Geleabert, Alexandra, Gerard, Laurent, Giménez, Josep Guitart, Gobardhan, Paul, Goffette, Pierre, Grochola, Lukasz Filip, Gruenberger, Thomas, Grünhagen, Dirk, Guiliante, Felice, Gómez, Fernando, Hagendoorn, Jeroen, Hammond, John, Heijmans, Margot, Heil, Jan, Heise, Daniel, Laurens Hermie, Herrero, Eric, Hess, Gebriel, Heye, Sam, Hoffmann, Martin, Iezzi, Roberto, Imani, Farshad, James, Sinead, Jardinet, Thomas, Joshi, Kunal, Jovine, Elio, Kalil, Jennifer, Karanicolas, Paul, Kazemier, Geert, Kern, Lars, Kingham, Peter, Klass, Darren, Koerkamp, Bas Groot, Kollmar, Otto, Korenblik, Remon, Choon Kwon, Céline Lambrecht, Sven Lang, Laura-Ann, Leclercq, Wouter, van der Leij, Christiaan, Lindsay, Richard, Lopez-Ben, Santiago, Lucidi, Valerio, López, Jordi Navinés, Macdonald, Andrew, Madoff, David C., Markose, George, Maroune, Gilbert, Martel, Guillaume, Martin, Ernesto Santos, Mehrzad, Homoyon, Meijerink, Martijn, Melloul, Emmanuel, Messaoudi, Nouredin, Metrakos, Peter, Modi, Sachin, Montanari, Nicola, Moragues, Jaume Sampere, Mujoomdar, Amol, Neumann, Ulf, Oor, Jelmer, Pappas, Patroklos, Pieterman, Kay, Primrose, John, Qu, Xudong, Ratti, Francesca, Ridouani, Fourat, Borel Rinkes, Inne H.M., Casellas i Robert, Margarida, Ross, Steffen, Ruo, Leyo, Ryan, Stephen, Salik, Aysun, Sandström, Per, Santol, Jonas, Sarría, Luis, Schaarschmidt, Benedikt, Schadde, Erik, Schiesser, Marc, Schmelzle, Moritz, Seeger, Nico, Segedi, Maja, Serenari, Matteo, Gregory Sergeant, Serrablo, Alejandro, Simon, Sorina, Skaro, Anton, Smits, Maarten, Smits, Jens, Snitzbauer, Andreas, Soonawalla, Zahir, Sparrelid, Ernesto, Spuentrup, Elmar, Stavrou, Gregor, Sutcliffe, Robert, Swijnenburg, Rutger-Jan, Tancredi, Ilario, Tasse, Jordan C., Tschögl, Madita, Udupa, Venkatesha, Valenti, David A., Vass, David, van der Velden, Ariadne Lisa, Vogl, Thomas, Wacker, Frank, Wang, Xiaoying, Weitz, Jürgen, White, Steven, Widyaningsih, Rizky, De Wispelaere, Jean-François, Zijlstra, Ijsbrand, Chau, Steven, James, Sinéad, Abreu de Carvalho, Luis, Erdmann, Joris, Hermie, Laurens, and van Dam, Ronald M.
- Published
- 2024
- Full Text
- View/download PDF
11. MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial
- Author
-
Ayez, Ninos, Bnà, Claudio, van den Boom, Rivka, Lambregts, Doenja J.M., Liefers, Gerrit-Jan, de Meyere, Celine, Draaisma, Werner A., Gerhards, Michael F., Imani, Farshad, Ruers, Theo .J.M., Liem, Mike S.L., Serafino, Gian Piero, van Beek, Hermen C., van der Hoeven, Joost A.B., Veeken, Cornelis J., Zonderhuis, Babs M., Görgec, Burak, Hansen, Ingrid S, Kemmerich, Gunter, Syversveen, Trygve, Abu Hilal, Mohammed, Belt, Eric J T, Bosscha, Koop, Burgmans, Mark C, Cappendijk, Vincent C, D'Hondt, Mathieu, Edwin, Bjørn, van Erkel, Arian R, Gielkens, Hugo A J, Grünhagen, Dirk J, Gobardhan, Paul D, Hartgrink, Henk H, Horsthuis, Karin, Klompenhouwer, Elisabeth G, Kok, Niels F M, Kint, Peter A M, Kuhlmann, Koert, Leclercq, Wouter K G, Lips, Daan J, Lutin, Bart, Maas, Monique, Marsman, Hendrik A, Meijerink, Martijn, Meyer, Yannick, Morone, Mario, Peringa, Jan, Sijberden, Jasper P, van Delden, Otto M, van den Bergh, Janneke E, Vanhooymissen, Inge J S, Vermaas, Maarten, Willemssen, François E J A, Dijkgraaf, Marcel G W, Bossuyt, Patrick M, Swijnenburg, Rutger-Jan, Fretland, Åsmund A, Verhoef, Cornelis, Besselink, Marc G, and Stoker, Jaap
- Published
- 2024
- Full Text
- View/download PDF
12. Trends and overall survival after combined liver resection and thermal ablation of colorectal liver metastases: a nationwide population-based propensity score-matched study
- Author
-
Buis, Carlijn I., Hagendoorn, Jeroen, Torrenga, Hans, van Heek, N. Tjarda, Braat, Andries E., Hoogwater, Frederik J.H., Consten, Esther C.J., van der Leij, Christiaan, Patijn, Gijs, de Graaff, Michelle R., Klaase, Joost M., den Dulk, Marcel, Coolsen, Marielle M.E., Kuhlmann, Koert F.D., Verhoef, Cees, Hartgrink, Henk H., Derksen, Wouter J.M., van den Boezem, Peter, Rijken, Arjen M., Gobardhan, Paul, Liem, Mike S.L., Leclercq, Wouter K.G., Marsman, Hendrik A., van Duijvendijk, Peter, Bosscha, Koop, Elfrink, Arthur K.E., Manusama, Eric R., Belt, Eric J. Th., Doornebosch, Pascal G., Oosterling, Steven J., Ruiter, Simeon J.S., Grünhagen, Dirk J., Burgmans, Mark, Meijerink, Martijn, Kok, Niels F.M., and Swijnenburg, Rutger-Jan
- Published
- 2024
- Full Text
- View/download PDF
13. Survival after Resection of Malignant Peripheral Nerve Sheath Tumors: introducing and validating a novel type-specific prognostic model
- Author
-
Acem, Ibtissam, primary, Steyerberg, Ewout W, additional, Spreafico, Marta, additional, Grünhagen, Dirk J, additional, Callegaro, Dario, additional, Spinner, Robert J, additional, Pendleton, Courtney, additional, Coert, J Henk, additional, Miceli, Rosalba, additional, Abruzzese, Giulia, additional, Flucke, Uta E, additional, Slooff, Willem-Bart M, additional, van Dalen, Thijs, additional, Been, Lukas B, additional, Bonenkamp, Han J, additional, Anten, Monique H M E, additional, Broen, Martinus P G, additional, Bemelmans, Marc H A, additional, Bramer, Jos A M, additional, Schaap, Gerard R, additional, Kievit, Arthur J, additional, van der Hage, Jos, additional, van Houdt, Winan J, additional, van de Sande, Michiel A J, additional, Gronchi, Alessandro, additional, Verhoef, Cornelis, additional, and Martin, Enrico, additional
- Published
- 2024
- Full Text
- View/download PDF
14. Improvement of perioperative outcomes of gastric gastrointestinal stromal tumour resections and the influence of minimal invasive surgery
- Author
-
van der Burg, Stijn JC., primary, Bleckman, Roos F., additional, van der Sluis, Pieter C., additional, Hartgrink, Henk H., additional, Reyners, An KL., additional, Bonenkamp, Johannes J., additional, van Sandick, Johanna W., additional, Wouters, Michel WJM., additional, van Houdt, Winan J., additional, Schrage, Yvonne M., additional, Hartemink, Koen J., additional, Steeghs, Neeltje, additional, Hakkesteegt, Stefanie N., additional, Grünhagen, Dirk J., additional, van Coevorden, Frits, additional, Mohammadi, Mahmoud, additional, Roets, Evelyne, additional, and van Etten, Boudewijn, additional
- Published
- 2024
- Full Text
- View/download PDF
15. Assessing quality of hepato-pancreato-biliary surgery: nationwide benchmarking
- Author
-
de Graaff, Michelle R, primary, Hendriks, Tessa E, additional, Wouters, Michel, additional, Nielen, Mark, additional, de Hingh, Ignace, additional, Koerkamp, Bas Groot, additional, van Santvoort, Hjalmar C, additional, Busch, Olivier R, additional, den Dulk, Marcel, additional, Klaase, Joost M, additional, van Zwet, Erik, additional, Bonsing, Bert A, additional, Grünhagen, Dirk J, additional, Besselink, Marc G, additional, and Kok, Niels F M, additional
- Published
- 2024
- Full Text
- View/download PDF
16. Feasibility, reliability and satisfaction of (automated) capillary carcinoembryonic antigen measurements for future home‐based blood sampling: the prospective CASA‐I study.
- Author
-
Voigt, Kelly R., Wullaert, Lissa, Gobardhan, P. D., Doornebosch, P. G., Verhoef, Cornelis, Husson, Olga, Ramakers, Christian, and Grünhagen, Dirk J.
- Subjects
PEARSON correlation (Statistics) ,BLOOD collection ,BLOOD sampling ,COLORECTAL cancer ,SATISFACTION ,PAIN measurement ,CARCINOEMBRYONIC antigen - Abstract
Aim: Follow‐up for colorectal cancer (CRC) necessitates regular monitoring of carcinoembryonic antigen (CEA) at the hospital. Capillary home‐based blood collection, including minimally invasive techniques such as lancet sampling or an automated upper arm device (TAP‐II), has the potential to replace a significant portion of hospital‐based blood sampling, thereby enhancing self‐reliance and quality of life. The objectives of this study were to assess the feasibility, reliability and preference for CEA blood collection. Methods: Baseline venous and capillary (by lancet and TAP‐II) blood samples were collected from 102 participants, including 20 CRC patients with elevated CEA levels, 60 CRC patients undergoing postoperative outpatient monitoring and 20 healthy volunteers. The second group performed capillary blood collections at home on two consecutive follow‐up appointments and subsequently sent them to the hospital. Satisfaction was assessed via patient reported outcome measures on pain, burden, ease of use and preference. Results: The Pearson's correlation test of all usable samples resulted in a linear coefficient of 0.998 (95% CI 0.997–0.998) for the TAP‐II method and 0.997 (95% CI 0.996–0.998) for the lancet method, both compared to venipuncture. Following the initial blood collection, 86% of the participants (n = 102) favoured the TAP‐II, rating it as the least painful and burdensome option. After two home‐based blood samples, the preference for the TAP‐II method persisted, with 64% of the patients endorsing its use. Conclusion: This study demonstrated the feasibility of home‐based capillary sampling of CEA. The TAP‐II blood collection is the most reliable method and is preferred by patients over venipuncture and lancet sampling. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Evaluating task-specific augmentations in self-supervised pre-training for 3D medical image analysis
- Author
-
Claessens, Cris, primary, Hamm, Julie, additional, Viviers, Christiaan G. A., additional, Nederend, Joost, additional, Grünhagen, Dirk, additional, Tanis, Pieter, additional, de With, Peter H. N., additional, and van der Sommen, Fons, additional
- Published
- 2024
- Full Text
- View/download PDF
18. The association of Cognitive Coping Style with Patient Preferences in a Patient- Led Follow-Up Study among Colorectal Cancer Survivors
- Author
-
Voigt, Kelly R., primary, Wullaert, Lissa, additional, Driel, M. H. Elise van, additional, Goudberg, Max, additional, Doornebosch, Pascal G., additional, Schreinemakers, Jennifer M.J., additional, Verseveld, Maria, additional, Peeters, Koen C.M.J., additional, Verhoef, Cornelis, additional, Husson, Olga, additional, and Grünhagen, Dirk J., additional
- Published
- 2024
- Full Text
- View/download PDF
19. Hospital variation and outcomes after repeat hepatic resection for colorectal liver metastases: a nationwide cohort study
- Author
-
de Graaff, Michelle R., primary, Klaase, Joost M., additional, den Dulk, Marcel, additional, te Riele, Wouter W., additional, Hagendoorn, Jeroen, additional, van Heek, N. Tjarda, additional, Vermaas, M., additional, Belt, Eric J. Th., additional, Bosscha, Koop, additional, Slooter, Gerrit D., additional, Leclercq, Wouter K.G., additional, Liem, Mike S.L., additional, Mieog, J. Sven D., additional, Swijnenburg, Rutger-Jan, additional, van Dam, Ronald M., additional, Verhoef, Cees, additional, Kuhlmann, Koert, additional, van Duijvendijk, Peter, additional, Gerhards, Michael F., additional, Gobardhan, Paul, additional, van den Boezem, Peter, additional, Manusama, Eric R., additional, Grünhagen, Dirk J., additional, Kok, Niels F.M., additional, and Torrenga, Hans, additional
- Published
- 2024
- Full Text
- View/download PDF
20. Outcomes of liver surgery: A decade of mandatory nationwide auditing in the Netherlands
- Author
-
de Graaff, Michelle R., primary, Klaase, Joost M., additional, Dulk, Marcel den, additional, Buis, C.I., additional, Derksen, Wouter J.M., additional, Hagendoorn, Jeroen, additional, Leclercq, Wouter K.G., additional, Liem, Mike S.L., additional, Hartgrink, Henk H., additional, Swijnenburg, Rutger-Jan, additional, Vermaas, M., additional, Belt, Eric J. Th, additional, Bosscha, Koop, additional, Verhoef, Cees, additional, Olde Damink, Steven, additional, Kuhlmann, Koert, additional, Marsman, H.M., additional, Ayez, Ninos, additional, van Duijvendijk, Peter, additional, van den Boezem, Peter, additional, Manusama, Eric R., additional, Grünhagen, Dirk J., additional, Kok, Niels F.M., additional, Patijn, Gijs A., additional, Torrenga, Hans, additional, van Heek, N. Tjarda, additional, and Oosterling, Steven J., additional
- Published
- 2024
- Full Text
- View/download PDF
21. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial
- Author
-
Bol, Kalijn F., primary, Schreibelt, Gerty, additional, Bloemendal, Martine, additional, van Willigen, Wouter W., additional, Hins-de Bree, Simone, additional, de Goede, Anna L., additional, de Boer, Annemiek J., additional, Bos, Kevin J. H., additional, Duiveman-de Boer, Tjitske, additional, Olde Nordkamp, Michel A. M., additional, van Oorschot, Tom G. M., additional, Popelier, Carlijn J., additional, Pots, Jeanne M., additional, Scharenborg, Nicole M., additional, van de Rakt, Mandy W. M. M., additional, de Ruiter, Valeska, additional, van Meeteren, Wilmy S., additional, van Rossum, Michelle M., additional, Croockewit, Sandra J., additional, Koeneman, Bouke J., additional, Creemers, Jeroen H. A., additional, Wortel, Inge M. N., additional, Angerer, Caroline, additional, Brüning, Mareke, additional, Petry, Katja, additional, Dzionek, Andrzej, additional, van der Veldt, Astrid A., additional, van Grünhagen, Dirk J., additional, Werner, Johanna E. M., additional, Bonenkamp, Johannes J., additional, Haanen, John B. A. G., additional, Boers-Sonderen, Marye J., additional, Koornstra, Rutger H. T., additional, Boomsma, Martijn F., additional, Aarntzen, Erik H. J., additional, Gotthardt, Martin, additional, Nagarajah, James, additional, de Witte, Theo J. M., additional, Figdor, Carl G., additional, de Wilt, Johannes H. W., additional, Textor, Johannes, additional, de Groot, Jan Willem B., additional, Gerritsen, Winald R., additional, and de Vries, I. Jolanda M., additional
- Published
- 2024
- Full Text
- View/download PDF
22. Referral patterns of GIST patients: data from a nationwide study
- Author
-
Roets, Evelyne, primary, Ijzerman, Nikki S., additional, Ho, Vincent K.Y., additional, Desar, Ingrid M.E., additional, Reyners, Anna K.L., additional, Gelderblom, Hans, additional, Grünhagen, Dirk J., additional, Van Etten, Boudewijn, additional, Van Houdt, Winan J., additional, Van der Graaf, Winette T.A., additional, and Steeghs, Neeltje, additional
- Published
- 2024
- Full Text
- View/download PDF
23. Association of modified textbook outcome and overall survival after surgery for colorectal liver metastases:A nationwide analysis
- Author
-
Voigt, Kelly R., de Graaff, Michelle R., Verhoef, Cornelis, Kazemier, Geert, Swijneburg, Rutger J., Mieog, J. Sven D., Derksen, Wouter J.M., Buis, Carlijn I., Gobardhan, Paul D., Dulk, Marcel den, van Dam, Ronald M., Liem, Mike S.L., Leclercq, Wouter K.G., Bosscha, Koop, Belt, Eric J.T., Vermaas, Maarten, Kok, Niels F.M., Patijn, Gijs A., Marsman, H. M., van den Boezem, Peter B., Klaase, Joost M., Grünhagen, Dirk J., Voigt, Kelly R., de Graaff, Michelle R., Verhoef, Cornelis, Kazemier, Geert, Swijneburg, Rutger J., Mieog, J. Sven D., Derksen, Wouter J.M., Buis, Carlijn I., Gobardhan, Paul D., Dulk, Marcel den, van Dam, Ronald M., Liem, Mike S.L., Leclercq, Wouter K.G., Bosscha, Koop, Belt, Eric J.T., Vermaas, Maarten, Kok, Niels F.M., Patijn, Gijs A., Marsman, H. M., van den Boezem, Peter B., Klaase, Joost M., and Grünhagen, Dirk J.
- Abstract
Background: Textbook outcome (TO) represents a multidimensional quality measurement, encompassing the desirable short-term outcomes following surgery. This study aimed to investigate whether achieving TO after resection of colorectal liver metastases (CRLM) surgery is related to better overall survival (OS) in a national cohort. Method: Data was retrieved from the Dutch Hepato Biliary Audit. A modified definition of TO (mTO) was used because readmissions were only recorded from 2019. mTO was achieved when no severe postoperative complications, mortality, prolonged length of hospital stay, occurred and when adequate surgical resection margins were obtained. To compare outcomes of patients with and without mTO and reduce baseline differences between both groups propensity score matching (PSM) was used for patients operated on between 2014 and 2018. Results: Out of 6525 eligible patients, 81 % achieved mTO. For the cohort between 2014 and 2018, those achieving mTO had a 5-year OS of 46.7 % (CI 44.8–48.6) while non-mTO patients had a 5-year OS of 33.7 % (CI 29.8–38.2), p < 0.001. Not achieving mTO was associated with a worse OS (aHR 1.34 (95 % CI 1.17–1.53), p < 0.001. Median follow-up was 76 months., PSM assigned 519 patients to each group. In the PSM cohort patients achieving mTO, 5-year OS was 43.6 % (95 % CI 39.2–48.5) compared to 36.4 % (95 % CI 31.9–41.2) in patients who did not achieve mTO, p = 0.006. Conclusion: Achieving mTO is associated with improved long-term survival. This emphasizes the importance of optimising perioperative care and reducing postoperative complications in surgical treatment of CRLM.
- Published
- 2024
24. Trends and overall survival after combined liver resection and thermal ablation of colorectal liver metastases:a nationwide population-based propensity score-matched study
- Author
-
de Graaff, Michelle R., Klaase, Joost M., den Dulk, Marcel, Coolsen, Marielle M.E., Kuhlmann, Koert F.D., Verhoef, Cees, Hartgrink, Henk H., Derksen, Wouter J.M., van den Boezem, Peter, Rijken, Arjen M., Gobardhan, Paul, Liem, Mike S.L., Leclercq, Wouter K.G., Marsman, Hendrik A., van Duijvendijk, Peter, Bosscha, Koop, Elfrink, Arthur K.E., Manusama, Eric R., Belt, Eric J.Th, Doornebosch, Pascal G., Oosterling, Steven J., Ruiter, Simeon J.S., Grünhagen, Dirk J., Burgmans, Mark, Meijerink, Martijn, Kok, Niels F.M., Swijnenburg, Rutger Jan, Buis, Carlijn I., Hagendoorn, Jeroen, Torrenga, Hans, van Heek, N. Tjarda, Braat, Andries E., Hoogwater, Frederik J.H., Consten, Esther C.J., van der Leij, Christiaan, Patijn, Gijs, de Graaff, Michelle R., Klaase, Joost M., den Dulk, Marcel, Coolsen, Marielle M.E., Kuhlmann, Koert F.D., Verhoef, Cees, Hartgrink, Henk H., Derksen, Wouter J.M., van den Boezem, Peter, Rijken, Arjen M., Gobardhan, Paul, Liem, Mike S.L., Leclercq, Wouter K.G., Marsman, Hendrik A., van Duijvendijk, Peter, Bosscha, Koop, Elfrink, Arthur K.E., Manusama, Eric R., Belt, Eric J.Th, Doornebosch, Pascal G., Oosterling, Steven J., Ruiter, Simeon J.S., Grünhagen, Dirk J., Burgmans, Mark, Meijerink, Martijn, Kok, Niels F.M., Swijnenburg, Rutger Jan, Buis, Carlijn I., Hagendoorn, Jeroen, Torrenga, Hans, van Heek, N. Tjarda, Braat, Andries E., Hoogwater, Frederik J.H., Consten, Esther C.J., van der Leij, Christiaan, and Patijn, Gijs
- Abstract
Background: In colorectal liver metastases (CRLM) patients, combination of liver resection and ablation permit a more parenchymal-sparing approach. This study assessed trends in use of combined resection and ablation, outcomes, and overall survival (OS). Methods: This population-based study included all CRLM patients who underwent liver resection between 2014 and 2022. To assess OS, data was linked to two databases containing date of death for patients treated between 2014 and 2018. Hospital variation in the use of combined minor liver resection and ablation versus major liver resection alone in patients with 2–3 CRLM and ≤3 cm was assessed. Propensity score matching (PSM) was applied to evaluate outcomes. Results: This study included 3593 patients, of whom 1336 (37.2%) underwent combined resection and ablation. Combined resection increased from 31.7% in 2014 to 47.9% in 2022. Significant hospital variation (range 5.9–53.8%) was observed in the use of combined minor liver resection and ablation. PSM resulted in 1005 patients in each group. Major morbidity was not different (11.6% vs. 5%, P = 1.00). Liver failure occurred less often after combined resection and ablation (1.9% vs. 0.6%, P = 0.017). Five-year OS rates were not different (39.3% vs. 33.9%, P = 0.145). Conclusion: Combined resection and ablation should be available and considered as an alternative to resection alone in any patient with multiple metastases.
- Published
- 2024
25. Extrahepatic perfusion and incomplete hepatic perfusion after hepatic arterial infusion pump implantation:incidence and clinical implications
- Author
-
Filipe, Wills F, Buisman, Florian E, Franssen, Stijn, Krul, Myrtle F, Grünhagen, Dirk J, Bennink, Roel J, Bolhuis, Karen, Bruijnen, Rutger C G, Buffart, Tineke E, Burgmans, Mark C, van Delden, Otto M, Doornebosch, Pascal G, Gobardhan, Paul D, Graven, Laura, de Groot, Jan Willem B, Grootscholten, Cecile, Hagendoorn, Jeroen, Harmsen, Paul, Homs, Marjolein Y V, Klompenhouwer, Elizabeth G, Kok, Niels F M, Lam, Marnix G E H, Loosveld, Olaf J L, Meier, Mark A J, Mieog, J Sven D, Oostdijk, Ad H J, Outmani, Loubna, Patijn, Gijs A, Pool, Stefan, Rietbergen, Daphne D D, Roodhart, Jeanine M L, Speetjens, Frank M, Swijnenburg, Rutger Jan, Versleijen, Michelle W J, Verhoef, Cornelis, Kuhlmann, Koert F D, Moelker, Adriaan, Groot Koerkamp, Bas, Filipe, Wills F, Buisman, Florian E, Franssen, Stijn, Krul, Myrtle F, Grünhagen, Dirk J, Bennink, Roel J, Bolhuis, Karen, Bruijnen, Rutger C G, Buffart, Tineke E, Burgmans, Mark C, van Delden, Otto M, Doornebosch, Pascal G, Gobardhan, Paul D, Graven, Laura, de Groot, Jan Willem B, Grootscholten, Cecile, Hagendoorn, Jeroen, Harmsen, Paul, Homs, Marjolein Y V, Klompenhouwer, Elizabeth G, Kok, Niels F M, Lam, Marnix G E H, Loosveld, Olaf J L, Meier, Mark A J, Mieog, J Sven D, Oostdijk, Ad H J, Outmani, Loubna, Patijn, Gijs A, Pool, Stefan, Rietbergen, Daphne D D, Roodhart, Jeanine M L, Speetjens, Frank M, Swijnenburg, Rutger Jan, Versleijen, Michelle W J, Verhoef, Cornelis, Kuhlmann, Koert F D, Moelker, Adriaan, and Groot Koerkamp, Bas
- Abstract
INTRODUCTION: This study investigates the incidence of extrahepatic perfusion and incomplete hepatic perfusion at intraoperative methylene blue testing and on postoperative nuclear imaging in patients undergoing hepatic arterial infusion pump (HAIP) chemotherapy.METHODS:The first 150 consecutive patients who underwent pump implantation in the Netherlands were included. All patients underwent surgical pump implantation with the catheter in the gastroduodenal artery. All patients underwent intraoperative methylene blue testing and postoperative nuclear imaging ( 99mTc-Macroaggregated albumin SPECT/CT) to determine perfusion via the pump. RESULTS: Patients were included between January-2018 and December-2021 across eight centers. During methylene blue testing, 29.3% had extrahepatic perfusion, all successfully managed intraoperatively. On nuclear imaging, no clinically relevant extrahepatic perfusion was detected (0%, 95%CI: 0.0-2.5%). During methylene blue testing, 2.0% had unresolved incomplete hepatic perfusion. On postoperative nuclear imaging, 8.1% had incomplete hepatic perfusion, leading to embolization in only 1.3%.CONCLUSION: Methylene blue testing during pump placement for intra-arterial chemotherapy identified extrahepatic perfusion in 29.3% of patients, but could be resolved intraoperatively in all patients. Postoperative nuclear imaging found no clinically relevant extrahepatic perfusion and led to embolization in only 1.3% of patients. The role of routine nuclear imaging after HAIP implantation should be studied in a larger cohort.
- Published
- 2024
26. Hospital variation and outcomes after repeat hepatic resection for colorectal liver metastases:a nationwide cohort study
- Author
-
de Graaff, Michelle R., Klaase, Joost M., den Dulk, Marcel, te Riele, Wouter W., Hagendoorn, Jeroen, van Heek, N. Tjarda, Vermaas, M., Belt, Eric J.Th, Bosscha, Koop, Slooter, Gerrit D., Leclercq, Wouter K.G., Liem, Mike S.L., Mieog, J. Sven D., Swijnenburg, Rutger Jan, van Dam, Ronald M., Verhoef, Cees, Kuhlmann, Koert, van Duijvendijk, Peter, Gerhards, Michael F., Gobardhan, Paul, van den Boezem, Peter, Manusama, Eric R., Grünhagen, Dirk J., Kok, Niels F.M., Torrenga, Hans, de Graaff, Michelle R., Klaase, Joost M., den Dulk, Marcel, te Riele, Wouter W., Hagendoorn, Jeroen, van Heek, N. Tjarda, Vermaas, M., Belt, Eric J.Th, Bosscha, Koop, Slooter, Gerrit D., Leclercq, Wouter K.G., Liem, Mike S.L., Mieog, J. Sven D., Swijnenburg, Rutger Jan, van Dam, Ronald M., Verhoef, Cees, Kuhlmann, Koert, van Duijvendijk, Peter, Gerhards, Michael F., Gobardhan, Paul, van den Boezem, Peter, Manusama, Eric R., Grünhagen, Dirk J., Kok, Niels F.M., and Torrenga, Hans
- Abstract
Background: Approximately 70% of patients with colorectal liver metastases (CRLM) experiences intrahepatic recurrence after initial liver resection. This study assessed outcomes and hospital variation in repeat liver resections (R-LR).Methods: This population-based study included all patients who underwent liver resection for CRLM between 2014 and 2022 in the Netherlands. Overall survival (OS) was collected for patients operated on between 2014 and 2018 by linkage to the insurance database. Results: Data of 7479 liver resections (1391 (18.6%) repeat and 6088 (81.4%) primary) were analysed. Major morbidity and mortality were not different. Factors associated with major morbidity included ASA 3+, major liver resection, extrahepatic disease, and open surgery. Five-year OS after repeat versus primary liver resection was 42.3% versus 44.8%, P = 0.37. Factors associated with worse OS included largest CRLM >5 cm (aHR 1.58, 95% CI: 1.07–2.34, P = 0.023), >3 CRLM (aHR 1.33, 95% CI: 1.00–1.75, P = 0.046), extrahepatic disease (aHR 1.60, 95% CI: 1.25–2.04, P = 0.001), positive tumour margins (aHR 1.42, 95% CI: 1.09–1.85, P = 0.009). Significant hospital variation in performance of R-LR was observed, median 18.9% (8.2% to 33.3%).Conclusion: Significant hospital variation was observed in performance of R-LR in the Netherlands reflecting different treatment decisions upon recurrence. On a population-based level R-LR leads to satisfactory survival.
- Published
- 2024
27. Outcomes of liver surgery:A decade of mandatory nationwide auditing in the Netherlands
- Author
-
de Graaff, Michelle R., Klaase, Joost M., Dulk, Marcel den, Buis, C. I., Derksen, Wouter J.M., Hagendoorn, Jeroen, Leclercq, Wouter K.G., Liem, Mike S.L., Hartgrink, Henk H., Swijnenburg, Rutger Jan, Vermaas, M., Belt, Eric J.Th, Bosscha, Koop, Verhoef, Cees, Olde Damink, Steven, Kuhlmann, Koert, Marsman, H. M., Ayez, Ninos, van Duijvendijk, Peter, van den Boezem, Peter, Manusama, Eric R., Grünhagen, Dirk J., Kok, Niels F.M., Patijn, Gijs A., Torrenga, Hans, van Heek, N. Tjarda, Oosterling, Steven J., de Graaff, Michelle R., Klaase, Joost M., Dulk, Marcel den, Buis, C. I., Derksen, Wouter J.M., Hagendoorn, Jeroen, Leclercq, Wouter K.G., Liem, Mike S.L., Hartgrink, Henk H., Swijnenburg, Rutger Jan, Vermaas, M., Belt, Eric J.Th, Bosscha, Koop, Verhoef, Cees, Olde Damink, Steven, Kuhlmann, Koert, Marsman, H. M., Ayez, Ninos, van Duijvendijk, Peter, van den Boezem, Peter, Manusama, Eric R., Grünhagen, Dirk J., Kok, Niels F.M., Patijn, Gijs A., Torrenga, Hans, van Heek, N. Tjarda, and Oosterling, Steven J.
- Abstract
Background: In 2013, the nationwide Dutch Hepato Biliary Audit (DHBA) was initiated. The aim of this study was to evaluate changes in indications for and outcomes of liver surgery in the last decade. Methods: This nationwide study included all patients who underwent liver surgery for four indications, including colorectal liver metastases (CRLM), hepatocellular carcinoma (HCC), and intrahepatic– and perihilar cholangiocarcinoma (iCCA – pCCA) between 2014 and 2022. Trends in postoperative outcomes were evaluated separately for each indication using multilevel multivariable logistic regression analyses. Results: This study included 8057 procedures for CRLM, 838 for HCC, 290 for iCCA, and 300 for pCCA. Over time, these patients had higher risk profiles (more ASA-III patients and more comorbidities). Adjusted mortality decreased over time for CRLM, HCC and iCCA, respectively aOR 0.83, 95%CI 0.75–0.92, P < 0.001; aOR 0.86, 95%CI 0.75–0.99, P = 0.045; aOR 0.40, 95%CI 0.20–0.73, P < 0.001. Failure to rescue (FTR) also decreased for these groups, respectively aOR 0.84, 95%CI 0.76–0.93, P = 0.001; aOR 0.81, 95%CI 0.68–0.97, P = 0.024; aOR 0.29, 95%CI 0.08–0.84, P = 0.021). For iCCA severe complications (aOR 0.65 95%CI 0.43–0.99, P = 0.043) also decreased. No significant outcome differences were observed in pCCA. The number of centres performing liver resections decreased from 26 to 22 between 2014 and 2022, while median annual volumes did not change (40–49, P = 0.66). Conclusion: Over time, postoperative mortality and FTR decreased after liver surgery, despite treating higher-risk patients. The DHBA continues its focus on providing feedback and benchmark results to further enhance outcomes.
- Published
- 2024
28. Local recurrence in malignant peripheral nerve sheath tumours:multicentre cohort study
- Author
-
Jansma, Christianne Y.M.N., Acem, Ibtissam, Grünhagen, Dirk J., Verhoef, Cornelis, Martin, Enrico, Jansma, Christianne Y.M.N., Acem, Ibtissam, Grünhagen, Dirk J., Verhoef, Cornelis, and Martin, Enrico
- Abstract
BACKGROUND: Malignant peripheral nerve sheath tumours (MPNSTs) have high local recurrence (LR) rates. Literature varies on LR risk factors and treatment. This study aimed to elucidate treatment options and risk factors for first and second LRs (LR1 and LR2) in a large multicentre cohort. METHOD: Surgically treated primary MPNSTs between 1988 and 2019 in the MONACO multicentre cohort were included. Cox regression analysed LR1 and LR2 risk factors and overall survival (OS) after LR1. Treatment of LR1 and LR2 was evaluated. RESULTS: Among 507 patients, 28% developed LR1. Median follow-up was 66.9 months, and for survivors 111.1 months. Independent LR1 risk factors included high-grade tumours (HR 2.63; 95% c.i. 1.15 to 5.99), microscopically positive margins (HR 2.19; 95% c.i. 1.51 to 3.16) and large tumour size (HR 2.14; 95% c.i. 1.21 to 3.78). Perioperative radiotherapy (HR 0.62; 95% c.i. 0.43 to 0.89) reduced the risk. LR1 patients had poorer OS. Synchronous metastasis worsened OS (HR 1.79; 95% c.i. 1.02 to 3.14) post-LR1, while surgically treated LR was associated with better OS (HR 0.38; 95% c.i. 0.22 to 0.64) compared to non-surgical cases. Two-year survival after surgical treatment was 71% (95% c.i. 63 to 82%) versus 28% (95% c.i. 18 to 44%) for non-surgical LR1 patients. Most LR1 (75.4%) and LR2 (73.7%) patients received curative-intent treatment, often surgery alone (64.9% versus 47.4%). Radiotherapy combined with surgery was given to 11.3% of LR1 and 7.9% of LR2 patients. CONCLUSION: Large, high-grade MPNSTs with R1 resections are at higher LR1 risk, potentially reduced by radiotherapy. Surgically treated recurrences may provide improved survival in highly selected cases.
- Published
- 2024
29. The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases:An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial)
- Author
-
Holmberg, Carl Jacob, Zijlker, Lisanne P., Katsarelias, Dimitrios, Huibers, Anne E., Wouters, Michel W.J.M., Schrage, Yvonne, Reijers, Sophie J.M., van Thienen, Johannes V., Grünhagen, Dirk J., Martner, Anna, Nilsson, Jonas A., van Akkooi, Alexander C.J., Ny, Lars, van Houdt, Winan J., Bagge, Roger Olofsson, Holmberg, Carl Jacob, Zijlker, Lisanne P., Katsarelias, Dimitrios, Huibers, Anne E., Wouters, Michel W.J.M., Schrage, Yvonne, Reijers, Sophie J.M., van Thienen, Johannes V., Grünhagen, Dirk J., Martner, Anna, Nilsson, Jonas A., van Akkooi, Alexander C.J., Ny, Lars, van Houdt, Winan J., and Bagge, Roger Olofsson
- Abstract
Objective: ILP has shown to achieve high response rates in patients with melanoma ITM. Possibly there is a synergistic mechanism of action of ILP and anti-PD1. The aim of this trial was to investigate the safety and efficacy of adding a single dose of systemic anti-PD1 to isolated limb perfusion (ILP) for patients with melanoma in-transit metastases (ITM). Methods: In this placebo controlled double-blind phase Ib/II trial, patients with melanoma ITM were randomized 1:1 to either a single systemic dose of nivolumab or placebo one day prior to ILP. The primary endpoint was complete response (CR) rate at three months, and safety in terms of incidence and severity of adverse events (AEs). Results: A total of 20 patients were included. AEs of any grade occurred in 90% of patients in the nivolumab arm and in 80% in the placebo arm within three months after ILP. Grade 3 AEs were reported in 40% and 30% respectively, most commonly related to wound infection, wound dehiscence, or skin necrosis. There were no grade 4 or 5 AEs reported. The CR rate was 75% in the nivolumab arm and 60% in the placebo arm. The 1-year local progression-free rate was 86% in the nivolumab arm and 67% in the placebo arm. The 1-year OS was 100% in both arms. Conclusion: For patients with melanoma ITM, the addition of a single systemic dose of nivolumab the day before ILP is considered safe and feasible with promising efficacy. Accrual will continue in a phase 2 trial.
- Published
- 2024
30. Adjuvant dendritic cell therapy in stage IIIB/C melanoma:the MIND-DC randomized phase III trial
- Author
-
Bol, Kalijn F., Schreibelt, Gerty, Bloemendal, Martine, van Willigen, Wouter W., Hins-de Bree, Simone, de Goede, Anna L., de Boer, Annemiek J., Bos, Kevin J.H., Duiveman-de Boer, Tjitske, Olde Nordkamp, Michel A.M., van Oorschot, Tom G.M., Popelier, Carlijn J., Pots, Jeanne M., Scharenborg, Nicole M., van de Rakt, Mandy W.M.M., de Ruiter, Valeska, van Meeteren, Wilmy S., van Rossum, Michelle M., Croockewit, Sandra J., Koeneman, Bouke J., Creemers, Jeroen H.A., Wortel, Inge M.N., Angerer, Caroline, Brüning, Mareke, Petry, Katja, Dzionek, Andrzej, van der Veldt, Astrid A., van Grünhagen, Dirk J., Werner, Johanna E.M., Bonenkamp, Johannes J., Haanen, John B.A.G., Boers-Sonderen, Marye J., Koornstra, Rutger H.T., Boomsma, Martijn F., Aarntzen, Erik H.J., Gotthardt, Martin, Nagarajah, James, de Witte, Theo J.M., Figdor, Carl G., de Wilt, Johannes H.W., Textor, Johannes, de Groot, Jan Willem B., Gerritsen, Winald R., de Vries, I. Jolanda M., Bol, Kalijn F., Schreibelt, Gerty, Bloemendal, Martine, van Willigen, Wouter W., Hins-de Bree, Simone, de Goede, Anna L., de Boer, Annemiek J., Bos, Kevin J.H., Duiveman-de Boer, Tjitske, Olde Nordkamp, Michel A.M., van Oorschot, Tom G.M., Popelier, Carlijn J., Pots, Jeanne M., Scharenborg, Nicole M., van de Rakt, Mandy W.M.M., de Ruiter, Valeska, van Meeteren, Wilmy S., van Rossum, Michelle M., Croockewit, Sandra J., Koeneman, Bouke J., Creemers, Jeroen H.A., Wortel, Inge M.N., Angerer, Caroline, Brüning, Mareke, Petry, Katja, Dzionek, Andrzej, van der Veldt, Astrid A., van Grünhagen, Dirk J., Werner, Johanna E.M., Bonenkamp, Johannes J., Haanen, John B.A.G., Boers-Sonderen, Marye J., Koornstra, Rutger H.T., Boomsma, Martijn F., Aarntzen, Erik H.J., Gotthardt, Martin, Nagarajah, James, de Witte, Theo J.M., Figdor, Carl G., de Wilt, Johannes H.W., Textor, Johannes, de Groot, Jan Willem B., Gerritsen, Winald R., and de Vries, I. Jolanda M.
- Abstract
Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were randomized to adjuvant treatment with nDCs (n = 99) or placebo (n = 49). Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens. The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas the secondary endpoints included median RFS, 2-year and median overall survival, adverse event profile, and immunological response The 2-year RFS rate was 36.8% in the nDC treatment group and 46.9% in the control group (p = 0.31). Median RFS was 12.7 months vs 19.9 months, respectively (hazard ratio 1.25; 90% CI: 0.88−1.79; p = 0.29). Median overall survival was not reached in both treatment groups (hazard ratio 1.32; 90% CI: 0.73−2.38; p = 0.44). Grade 3−4 study-related adverse events occurred in 5% and 6% of patients. Functional antigen-specific T cell responses could be detected in 67.1% of patients tested in the nDC treatment group vs 3.8% of patients tested in the control group (p < 0.001). In conclusion, while adjuvant nDC treatment in stage IIIB/C melanoma patients generated specific immune responses and was well tolerated, no benefit in RFS was observed.
- Published
- 2024
31. Referral patterns of GIST patients:data from a nationwide study
- Author
-
Roets, Evelyne, Ijzerman, Nikki S., Ho, Vincent K.Y., Desar, Ingrid M.E., Reyners, Anna K.L., Gelderblom, Hans, Grünhagen, Dirk J., Van Etten, Boudewijn, Van Houdt, Winan J., Van der Graaf, Winette T.A., Steeghs, Neeltje, Roets, Evelyne, Ijzerman, Nikki S., Ho, Vincent K.Y., Desar, Ingrid M.E., Reyners, Anna K.L., Gelderblom, Hans, Grünhagen, Dirk J., Van Etten, Boudewijn, Van Houdt, Winan J., Van der Graaf, Winette T.A., and Steeghs, Neeltje
- Abstract
BACKGROUND: This study compares the characteristics, referral and treatment patterns and overall survival (OS) of gastrointestinal stromal tumor (GIST) patients treated in reference and non-reference centers in the Netherlands. PATIENTS AND METHODS: This retrospective cohort study on patients diagnosed between 2016 and 2019, utilises data from the Netherlands Cancer Registry and the Dutch Nationwide Pathology Database. Patients were categorized into two groups: patients diagnosed in or referred to reference centers and patients diagnosed in non-reference centers without referral. RESULTS: This study included 1,550 GIST patients with a median age of 67.0 in reference and 68.0 years in non-reference centers. Eighty-seven per cent of patients were diagnosed in non-reference centers, of which 36.5% (493/1,352) were referred to a reference center. Referral rates were higher for high-risk (62.2% [74/119]) and metastatic patients (67.2% [90/134]). Mutation analysis was performed in 96.9% and 87.6% of these cases in reference and in non-reference centers (p < 0.01), respectively. Systemic therapy was given in reference centers versus non-reference in 89.5% versus 82.0% (p < 0.01) of high-risk and in 94.1% versus 65.9% (p < 0.01) of metastatic patients, respectively. The proportion of positive resection margins and tumor rupture did not differ between reference and non-reference centers. Median OS was not reached. CONCLUSION: A substantial amount of metastatic GIST patients in non-reference centers did not receive systemic treatment. This might be due to valid reasons. However, optimisation of the referral strategy of GIST patients in the Netherlands could benefit patients. Further research is needed to explore reasons for not starting systemic treatment in metastatic GIST patients.
- Published
- 2024
32. Author response to:Oncological surgery follow-up and quality of life: meta-analysis
- Author
-
Wullaert, Lissa, Voigt, Kelly R., Verhoef, Cornelis, Husson, Olga, Grünhagen, Dirk J., Wullaert, Lissa, Voigt, Kelly R., Verhoef, Cornelis, Husson, Olga, and Grünhagen, Dirk J.
- Published
- 2024
33. Author response to: Comment on: Oncological surgery follow-up and quality of life: meta-analysis
- Author
-
Wullaert, Lissa, primary, Voigt, Kelly R, additional, Verhoef, Cornelis, additional, Husson, Olga, additional, and Grünhagen, Dirk J, additional
- Published
- 2024
- Full Text
- View/download PDF
34. Association of modified textbook outcome and overall survival after surgery for colorectal liver metastases: A nationwide analysis
- Author
-
Voigt, Kelly R., primary, de Graaff, Michelle R., additional, Verhoef, Cornelis, additional, Kazemier, Geert, additional, Swijneburg, Rutger J., additional, Mieog, J.Sven D., additional, Derksen, Wouter J.M., additional, Buis, Carlijn I., additional, Gobardhan, Paul D., additional, Dulk, Marcel den, additional, van Dam, RonaldM., additional, Liem, Mike S.L., additional, Leclercq, Wouter K.G., additional, Bosscha, Koop, additional, Belt, Eric J.T., additional, Vermaas, Maarten, additional, Kok, Niels F.M., additional, Patijn, Gijs A., additional, Marsman, H.M., additional, van den Boezem, Peter B., additional, Klaase, Joost M., additional, Grünhagen, Dirk J., additional, Manusama, Hans Torrenga E., additional, van Heek, Tjarda N., additional, and Oosterling, S.J., additional
- Published
- 2024
- Full Text
- View/download PDF
35. Trends and overall survival after combined liver resection and thermal ablation of colorectal liver metastases: a nationwide population-based propensity score-matched study
- Author
-
de Graaff, Michelle R., primary, Klaase, Joost M., additional, den Dulk, Marcel, additional, Coolsen, Marielle M.E., additional, Kuhlmann, Koert F.D., additional, Verhoef, Cees, additional, Hartgrink, Henk H., additional, Derksen, Wouter J.M., additional, van den Boezem, Peter, additional, Rijken, Arjen M., additional, Gobardhan, Paul, additional, Liem, Mike S.L., additional, Leclercq, Wouter K.G., additional, Marsman, Hendrik A., additional, van Duijvendijk, Peter, additional, Bosscha, Koop, additional, Elfrink, Arthur K.E., additional, Manusama, Eric R., additional, Belt, Eric J. Th., additional, Doornebosch, Pascal G., additional, Oosterling, Steven J., additional, Ruiter, Simeon J.S., additional, Grünhagen, Dirk J., additional, Burgmans, Mark, additional, Meijerink, Martijn, additional, Kok, Niels F.M., additional, Swijnenburg, Rutger-Jan, additional, Buis, Carlijn I., additional, Hagendoorn, Jeroen, additional, Torrenga, Hans, additional, van Heek, N. Tjarda, additional, Braat, Andries E., additional, Hoogwater, Frederik J.H., additional, Consten, Esther C.J., additional, van der Leij, Christiaan, additional, and Patijn, Gijs, additional
- Published
- 2024
- Full Text
- View/download PDF
36. Local recurrence in malignant peripheral nerve sheath tumours: multicentre cohort study.
- Author
-
Jansma, Christianne Y M N, Acem, Ibtissam, Grünhagen, Dirk J, Verhoef, Cornelis, Martin, Enrico, and Collaborators, MONACO
- Subjects
PERIPHERAL nerve tumors ,PERIPHERAL nervous system ,COHORT analysis ,TUMORS ,OVERALL survival ,RADIOTHERAPY - Abstract
Background Malignant peripheral nerve sheath tumours (MPNSTs) have high local recurrence (LR) rates. Literature varies on LR risk factors and treatment. This study aimed to elucidate treatment options and risk factors for first and second LRs (LR1 and LR2) in a large multicentre cohort. Method Surgically treated primary MPNSTs between 1988 and 2019 in the MONACO multicentre cohort were included. Cox regression analysed LR1 and LR2 risk factors and overall survival (OS) after LR1. Treatment of LR1 and LR2 was evaluated. Results Among 507 patients, 28% developed LR1. Median follow-up was 66.9 months, and for survivors 111.1 months. Independent LR1 risk factors included high-grade tumours (HR 2.63; 95% c.i. 1.15 to 5.99), microscopically positive margins (HR 2.19; 95% c.i. 1.51 to 3.16) and large tumour size (HR 2.14; 95% c.i. 1.21 to 3.78). Perioperative radiotherapy (HR 0.62; 95% c.i. 0.43 to 0.89) reduced the risk. LR1 patients had poorer OS. Synchronous metastasis worsened OS (HR 1.79; 95% c.i. 1.02 to 3.14) post-LR1, while surgically treated LR was associated with better OS (HR 0.38; 95% c.i. 0.22 to 0.64) compared to non-surgical cases. Two-year survival after surgical treatment was 71% (95% c.i. 63 to 82%) versus 28% (95% c.i. 18 to 44%) for non-surgical LR1 patients. Most LR1 (75.4%) and LR2 (73.7%) patients received curative-intent treatment, often surgery alone (64.9% versus 47.4%). Radiotherapy combined with surgery was given to 11.3% of LR1 and 7.9% of LR2 patients. Conclusion Large, high-grade MPNSTs with R1 resections are at higher LR1 risk, potentially reduced by radiotherapy. Surgically treated recurrences may provide improved survival in highly selected cases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Evaluation of surgical outcomes following gastric gastrointestinal stromal tumor (GIST) resections in the first thirteen years of the Dutch GIST registry
- Author
-
Van Der Burg, Stijn, Bleckman, Roos, Steeghs, Neeltje, Grünhagen, Dirk, Van Etten, Boudewijn, Reyners, An, Bonenkamp, Han, Hartgrink, Henk, Wouters, Michel, Van Houdt, Winan, and Schrage, Yvonne
- Published
- 2024
- Full Text
- View/download PDF
38. MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial.
- Author
-
Görgec, Burak, Hansen, Ingrid S, Kemmerich, Gunter, Syversveen, Trygve, Abu Hilal, Mohammed, Belt, Eric J T, Bosscha, Koop, Burgmans, Mark C, Cappendijk, Vincent C, D'Hondt, Mathieu, Edwin, Bjørn, van Erkel, Arian R, Gielkens, Hugo A J, Grünhagen, Dirk J, Gobardhan, Paul D, Hartgrink, Henk H, Horsthuis, Karin, Klompenhouwer, Elisabeth G, Kok, Niels F M, and Kint, Peter A M
- Subjects
- *
COLORECTAL liver metastasis , *CONTRAST-enhanced magnetic resonance imaging , *DIFFUSION magnetic resonance imaging , *CONTRAST media , *MAGNETIC resonance imaging - Abstract
Guidelines are inconclusive on whether contrast-enhanced MRI using gadoxetic acid and diffusion-weighted imaging should be added routinely to CT in the investigation of patients with colorectal liver metastases who are scheduled for curative liver resection or thermal ablation, or both. Although contrast-enhanced MRI is reportedly superior than contrast-enhanced CT in the detection and characterisation of colorectal liver metastases, its effect on clinical patient management is unknown. We aimed to assess the clinical effect of an additional liver contrast-enhanced MRI on local treatment plan in patients with colorectal liver metastases amenable to local treatment, based on contrast-enhanced CT. We did an international, multicentre, prospective, incremental diagnostic accuracy trial in 14 liver surgery centres in the Netherlands, Belgium, Norway, and Italy. Participants were aged 18 years or older with histological proof of colorectal cancer, a WHO performance status score of 0–4, and primary or recurrent colorectal liver metastases, who were scheduled for local therapy based on contrast-enhanced CT. All patients had contrast-enhanced CT and liver contrast-enhanced MRI including diffusion-weighted imaging and gadoxetic acid as a contrast agent before undergoing local therapy. The primary outcome was change in the local clinical treatment plan (decided by the individual clinics) on the basis of liver contrast-enhanced MRI findings, analysed in the intention-to-image population. The minimal clinically important difference in the proportion of patients who would have change in their local treatment plan due to an additional liver contrast-enhanced MRI was 10%. This study is closed and registered in the Netherlands Trial Register, NL8039. Between Dec 17, 2019, and July 31, 2021, 325 patients with colorectal liver metastases were assessed for eligibility. 298 patients were enrolled and included in the intention-to-treat population, including 177 males (59%) and 121 females (41%) with planned local therapy based on contrast-enhanced CT. A change in the local treatment plan based on liver contrast-enhanced MRI findings was observed in 92 (31%; 95% CI 26–36) of 298 patients. Changes were made for 40 patients (13%) requiring more extensive local therapy, 11 patients (4%) requiring less extensive local therapy, and 34 patients (11%) in whom the indication for curative-intent local therapy was revoked, including 26 patients (9%) with too extensive disease and eight patients (3%) with benign lesions on liver contrast-enhanced MRI (confirmed by a median follow-up of 21·0 months [IQR 17·5–24·0]). Liver contrast-enhanced MRI should be considered in all patients scheduled for local treatment for colorectal liver metastases on the basis of contrast-enhanced CT imaging. The Dutch Cancer Society and Bayer AG – Pharmaceuticals. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. [Less intensive follow-up after cancer is often equally effective].
- Author
-
Vos JAM, Swartjes H, and Grünhagen DJ
- Subjects
- Humans, Aftercare methods, Aftercare standards, Neoplasm Recurrence, Local, Prognosis, Patient Satisfaction, Neoplasms
- Abstract
Follow-up after cancer consists of regular check-ups, aimed at the early detection of recurrences, and aftercare. For most cancers, intensive follow-up strategies are recommended. However, for several cancer types, including breast and colorectal cancer, reducing the follow-up frequency has had no detrimental effects on outcomes such as survival (hazard ratio (HR) 1.05; 95%-BI: 0.96-1.14) and patient satisfaction. In cancers with a favorable prognosis, less intensive follow-up is likely to be equally effective, and can be personalized to individual needs. To do so, current follow-up guidelines must be critically reevaluated, and the benefits of performing regular check-ups should be investigated.
- Published
- 2024
40. Reply to: Pioneering combination: Nivolumab and isolated limb perfusion in melanoma in-transit metastases treatment.
- Author
-
Holmberg CJ, Zijlker LP, Katsarelias D, Huibers AE, Wouters MWJM, Schrage Y, Reijers SJM, van Thienen JV, Grünhagen DJ, Martner A, Nilsson JA, van Akkooi ACJ, Ny L, van Houdt WJ, and Olofsson Bagge R
- Abstract
Competing Interests: Declaration of competing interest Conflicts of interest: ACJvA is a member of the Advisory Board for, and received consultancy honoraria from, Amgen, Bristol-Myers Squibb, Neracare, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Provectus, Sanofi, Sirius Medical, and 4SC. WvH has received institutional honoraria, speakers honorarium, or institutional research grants from Amgen, Bristol-Myers Squibb, Novartis, MSD-Merck, Belpharma, Sanofi and Sirius Medical. ROB has received institutional research grants from Bristol-Myers Squibb (BMS) and SkyLineDx, speaker honorarium from Roche and Pfizer and has served on advisory boards for Amgen, BD/BARD, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Roche and Sanofi Genzyme. Remaining authors have no conflicts of interest to declare.
- Published
- 2024
- Full Text
- View/download PDF
41. Transcutaneous sentinel lymph node detection in skin melanoma with near-infrared fluorescence imaging using indocyanine green.
- Author
-
Zweedijk BE, Schurink AW, van Dalen T, van Ginhoven TM, Verhoef C, Kremer B, Hilling DE, Keereweer S, and Grünhagen DJ
- Abstract
The aim of the study is to assess whether indocyanine green (ICG) fluorescence can replace technetium in the preoperative detection of sentinel lymph nodes (SLN) from cutaneous melanoma. The current golden standard for SLN detection is the radioisotope technetium. A promising alternative is fluorescence imaging (FLI) using ICG. In this study, we enrolled patients undergoing sentinel lymph node biopsy (SLNB) for skin melanoma at the Erasmus Medical Center between November 2022 and July 2023. The SLNB procedure was performed as a standard of care. After general anesthesia, ICG was injected intradermally around the primary tumor site. Both the patient and the surgeon were not blinded for the location of the SLN. FLI was performed before incision, in vivo after incision, and ex vivo. Fluorescent SLNs were confirmed using the gamma probe in all cases. Thirty-two patients were included in this study, and a total of 39 SLNs were harvested. The transcutaneous detection rate of ICG was 21.9%. The combined ex vivo ICG fluorescence and technetium uptake was 94.9%. One SLN contained only ICG (2.6%) and one SLN contained only technetium-uptake (2.6%). FLI using ICG resulted in a relatively low transcutaneous detection, which means that exclusive use of this technique in its present form is not feasible. However, we did find a high accumulation of ICG in the SLN, indicating the potential of ICG in combination with other imaging techniques., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
42. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
- Author
-
Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, Hoeijmakers LL, Saw RPM, Lijnsvelt JM, Maher NG, Pulleman SM, Gonzalez M, Torres Acosta A, van Houdt WJ, Lo SN, Kuijpers AMJ, Spillane A, Klop WMC, Pennington TE, Zuur CL, Shannon KF, Seinstra BA, Rawson RV, Haanen JBAG, Ch'ng S, Naipal KAT, Stretch J, van Thienen JV, Rtshiladze MA, Wilgenhof S, Kapoor R, Meerveld-Eggink A, Grijpink-Ongering LG, van Akkooi ACJ, Reijers ILM, Gyorki DE, Grünhagen DJ, Speetjens FM, Vliek SB, Placzke J, Spain L, Stassen RC, Amini-Adle M, Lebbé C, Faries MB, Robert C, Ascierto PA, van Rijn R, van den Berkmortel FWPJ, Piersma D, van der Westhuizen A, Vreugdenhil G, Aarts MJB, Stevense-den Boer MAM, Atkinson V, Khattak M, Andrews MC, van den Eertwegh AJM, Boers-Sonderen MJ, Hospers GAP, Carlino MS, de Groot JB, Kapiteijn E, Suijkerbuijk KPM, Rutkowski P, Sandhu S, van der Veldt AAM, and Long GV
- Abstract
Background: Phase 1-2 trials involving patients with resectable, macroscopic stage III melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant immunotherapy., Methods: In this phase 3 trial, we randomly assigned patients with resectable, macroscopic stage III melanoma, in a 1:1 ratio, to receive two cycles of neoadjuvant ipilimumab plus nivolumab and then undergo surgery or to undergo surgery and then receive 12 cycles of adjuvant nivolumab. Only the patients in the neoadjuvant group who had a partial response or nonresponse received subsequent adjuvant treatment. The primary end point was event-free survival., Results: A total of 423 patients underwent randomization. At a median follow-up of 9.9 months, the estimated 12-month event-free survival was 83.7% (99.9% confidence interval [CI], 73.8 to 94.8) in the neoadjuvant group and 57.2% (99.9% CI, 45.1 to 72.7) in the adjuvant group. The difference in restricted mean survival time was 8.00 months (99.9% CI, 4.94 to 11.05; P<0.001; hazard ratio for progression, recurrence, or death, 0.32; 99.9% CI, 0.15 to 0.66). In the neoadjuvant group, 59.0% of the patients had a major pathological response, 8.0% had a partial response, 26.4% had a nonresponse (>50% residual viable tumor), and 2.4% had progression; in 4.2%, surgery had not yet been performed or was omitted. The estimated 12-month recurrence-free survival was 95.1% among patients in the neoadjuvant group who had a major pathological response, 76.1% among those who had a partial response, and 57.0% among those who had a nonresponse. Adverse events of grade 3 or higher that were related to systemic treatment occurred in 29.7% of the patients in the neoadjuvant group and in 14.7% in the adjuvant group., Conclusions: Among patients with resectable, macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab followed by surgery and response-driven adjuvant therapy resulted in longer event-free survival than surgery followed by adjuvant nivolumab. (Funded by Bristol Myers Squibb and others; NADINA ClinicalTrials.gov number, NCT04949113.)., (Copyright © 2024 Massachusetts Medical Society.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.